Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
Ovarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo-resistance. Thus, novel therapeutic approaches are required. Statins and amino...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
29 July 2020
|
| In: |
BMC cancer
Year: 2020, Volume: 20, Fascicolo: 1, Pages: 1-17 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-020-07164-x |
| Accesso online: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-020-07164-x Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1186/s12885-020-07164-x 
|
| Note sull'autore: | Andy Göbel, Valentina M. Zinna, Stefania Dell’Endice, Nikolai Jaschke, Jan Dominik Kuhlmann, Pauline Wimberger and Tilman D. Rachner |
| Riassunto: | Ovarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo-resistance. Thus, novel therapeutic approaches are required. Statins and amino-bisphosphonates are inhibitors of the mevalonate pathway, which is a fundamental pathway of cellular metabolism, essential for cholesterol production and posttranslational protein farnesylation and geranylgeranylation. While this pathway has emerged as a promising treatment target in several human malignancies, its potential as a therapeutic approach in ovarian cancer is still not fully understood. |
|---|---|
| Descrizione del documento: | Gesehen am 01.07.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-020-07164-x |